Old Web
English
Sign In
Acemap
>
authorDetail
>
P. Bartels
P. Bartels
Emory University
Melanoma
Phases of clinical research
Clinical endpoint
Chemotherapy
Toxicity
2
Papers
9
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma
2007
Journal of Clinical Oncology
Rene Gonzalez
Karl D. Lewis
Wolfram E. Samlowski
Lee D. Cranmer
Joseph P. Catlett
J. M. Kirkwood
Eric D. Whitman
David H. Lawson
P. Bartels
T. W. Drake
Show All
Source
Cite
Save
Citations (6)
A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.
2007
Molecular Cancer Therapeutics
Doru Alexandrescu
Rene Gonzales
Karl Lewis
Wolfram Samlowski
Lee Cranmer
Joseph Catlett
John Kirkwood
Eric Whitman
David H. Lawson
P. Bartels
Terry Drake
Anne Keating
Show All
Source
Cite
Save
Citations (3)
1